Table 3 Development of HF in patients with and without preserved EF
Study | Treatment | Total mortality events | Adjusted effect size [95% CI] | Covariates in effect size adjustment |
|---|---|---|---|---|
Masoudi et al. [20] | Metformin vs. No Insulin sensitiser | 4805 | HR 0.86 [0.77, 0.97] | Patient factors (such as age and gender), treating physician and hospital characteristics |
Romero et al. [21] | Metformin vs. No metformin | 1045 | HR 0.88 [0.83, 0.93] | Propensity matched: age, gender, educational level, social situation, occupation situation, type of HF, aetiology of HF, clinical signs, radiological data, ECG data, comorbidity, bloods (lipids, albumin, creatinine, eGFR, ACR, Hb, electrolyte levels), medication received, time to follow-up, place of diagnosis, income, early readmissions, time of hospitalisation, visits to medical professionals |
Facila et al. [19] | Metformin vs. No metformin | 382 | HR 0.68 [0.53, 0.87] | Age, gender, prior admission for AHF, prior history of stroke, PVD, HTN, QRS > 120 ms, LVEF, eGFR, Hb, NT pro-BNP, treatment with beta-blockers |
Aguilar et al. [18] | Metformin vs. No Metformin | 1423 | HR 0.76 [0.63, 0.92] | Propensity matched: Age, gender, race, BMI, SBP, DBP, LVEF, history of hypertension, PVD, CVD, AF, MI, cancer, COPD and diabetic complications, HF hospitalisation within the last 2Â years, bloods (Hb, HbA1c, sodium, urea, eGFR, total cholesterol and triglycerides) and treatment with beta-blockers, sulfonylurea, thiazolidinediones, insulin, statins, ACEi/ARB |